Documents tabled in the Senate today raised serious questions about the information provided on PBAC deferrals at Senate Estimates. The advice to Mark Butler indicates the committee's chair may have been indirectly involved in formulating the plan, that the department is legally required to evaluate submissions lodged for March regardless of capacity constraints, and that officials did not consult the industry as directed.
Publication of ministerial advice raises questions about the evidence given at Senate Estimates
November 29, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Biogen ANZ certified a 'Great Place to Work' for a fifth time
October 16, 2026 - - Latest News -
Tavneos to be withdrawn from Australia as CSL pulls vasculitis treatment
October 16, 2026 - - Latest News -
AI in HTA - survey reveals optimism and concern over a potential missed opportunity
October 16, 2026 - - Latest News -
England's chief scientific officer on the opportunity for Australia to get it right on genomics
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News
